# Therapeutic RSK1 Targeting in Myelofibrosis

> **NCT07379125** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 18 (estimated)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** PMD-026

## Key facts

- **NCT ID:** NCT07379125
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-31
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07379125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07379125, "Therapeutic RSK1 Targeting in Myelofibrosis". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT07379125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*